在PATHFINDER研究中,多种癌症早期检测测试对癌症信号起源预测和诊断解决的临床评价。

IF 2.6
Catherine R Marinac, Charles H McDonnell, Lincoln D Nadauld, Christina A Dilaveri, Robert Reid, Karen C Chung, Margarita Lopatin, Eric T Fung, Deborah Schrag, Rita Shaknovich, Eric A Klein
{"title":"在PATHFINDER研究中,多种癌症早期检测测试对癌症信号起源预测和诊断解决的临床评价。","authors":"Catherine R Marinac, Charles H McDonnell, Lincoln D Nadauld, Christina A Dilaveri, Robert Reid, Karen C Chung, Margarita Lopatin, Eric T Fung, Deborah Schrag, Rita Shaknovich, Eric A Klein","doi":"10.1158/1940-6207.CAPR-24-0468","DOIUrl":null,"url":null,"abstract":"<p><p>Blood-based multicancer early detection (MCED) tests represent a new approach for cancer detection. To gain insights into the utility of various approaches of evaluating a cancer signal detected (CSD) test result, we evaluated diagnostic journeys of a subset of 6,662 participants in PATHFINDER who had a CSD on both an initial and refined version of an MCED test that also provided a prediction of cancer signal origin (CSO). We sought to determine whether CSO prediction-guided diagnostic evaluations led to diagnostic resolution; whether participants with known risk factors for cancer beyond age alone and a negative initial diagnostic evaluation had a cancer diagnosis during study follow-up; the utility of whole-body imaging in reaching diagnostic resolution; and differences in the diagnostic journeys needed to reach diagnostic resolution for both true- and false-positive results. Of the 39 participants in this analysis, 82% (32/39) achieved diagnostic resolution after the initial evaluation, including 78% (25/32) who reached resolution specifically with a CSO prediction-directed workup. Eighteen percent (7/39) required additional evaluation for persistent clinical suspicion of cancer, all of whom achieved resolution (3 with and 4 without cancer). Whole-body imaging contributed to diagnostic resolution in only 49% of CSD cases. Approximately 90% of true- and false-positive cases had imaging tests; more true positives versus false positives (81.0% vs. 38.9%) had nonsurgical and/or surgical procedures. In conclusion, CSO prediction-directed evaluations enabled diagnostic resolution for most participants, although some with negative initial evaluations but persistent suspicion of cancer required additional testing.</p><p><strong>Prevention relevance: </strong>MCED testing has the potential to increase detection of cancer at earlier stages. As MCED testing is a new technology, there are few data on the diagnostic journeys patients undergo following testing. We observed that for most patients, CSO prediction-directed workups were efficient, leading to diagnostic resolution after initial evaluation.</p>","PeriodicalId":72514,"journal":{"name":"Cancer prevention research (Philadelphia, Pa.)","volume":" ","pages":"475-483"},"PeriodicalIF":2.6000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12314506/pdf/","citationCount":"0","resultStr":"{\"title\":\"Clinical Evaluation of Cancer Signal Origin Prediction and Diagnostic Resolution following Multicancer Early Detection Testing in the PATHFINDER Study.\",\"authors\":\"Catherine R Marinac, Charles H McDonnell, Lincoln D Nadauld, Christina A Dilaveri, Robert Reid, Karen C Chung, Margarita Lopatin, Eric T Fung, Deborah Schrag, Rita Shaknovich, Eric A Klein\",\"doi\":\"10.1158/1940-6207.CAPR-24-0468\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Blood-based multicancer early detection (MCED) tests represent a new approach for cancer detection. To gain insights into the utility of various approaches of evaluating a cancer signal detected (CSD) test result, we evaluated diagnostic journeys of a subset of 6,662 participants in PATHFINDER who had a CSD on both an initial and refined version of an MCED test that also provided a prediction of cancer signal origin (CSO). We sought to determine whether CSO prediction-guided diagnostic evaluations led to diagnostic resolution; whether participants with known risk factors for cancer beyond age alone and a negative initial diagnostic evaluation had a cancer diagnosis during study follow-up; the utility of whole-body imaging in reaching diagnostic resolution; and differences in the diagnostic journeys needed to reach diagnostic resolution for both true- and false-positive results. Of the 39 participants in this analysis, 82% (32/39) achieved diagnostic resolution after the initial evaluation, including 78% (25/32) who reached resolution specifically with a CSO prediction-directed workup. Eighteen percent (7/39) required additional evaluation for persistent clinical suspicion of cancer, all of whom achieved resolution (3 with and 4 without cancer). Whole-body imaging contributed to diagnostic resolution in only 49% of CSD cases. Approximately 90% of true- and false-positive cases had imaging tests; more true positives versus false positives (81.0% vs. 38.9%) had nonsurgical and/or surgical procedures. In conclusion, CSO prediction-directed evaluations enabled diagnostic resolution for most participants, although some with negative initial evaluations but persistent suspicion of cancer required additional testing.</p><p><strong>Prevention relevance: </strong>MCED testing has the potential to increase detection of cancer at earlier stages. As MCED testing is a new technology, there are few data on the diagnostic journeys patients undergo following testing. We observed that for most patients, CSO prediction-directed workups were efficient, leading to diagnostic resolution after initial evaluation.</p>\",\"PeriodicalId\":72514,\"journal\":{\"name\":\"Cancer prevention research (Philadelphia, Pa.)\",\"volume\":\" \",\"pages\":\"475-483\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2025-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12314506/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer prevention research (Philadelphia, Pa.)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1158/1940-6207.CAPR-24-0468\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer prevention research (Philadelphia, Pa.)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1158/1940-6207.CAPR-24-0468","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

基于血液的多种癌症早期检测(MCED)是一种新的癌症检测方法。为了深入了解评估癌症信号检测(CSD)测试结果的各种方法的效用,我们评估了PATHFINDER中6662名参与者的诊断过程,这些参与者在初始和改进版本的MCED测试中都有CSD,也提供了癌症信号起源(CSO)的预测。我们试图确定CSO预测引导的诊断评估是否导致诊断解决;在研究随访期间,已知癌症危险因素超过年龄且初始诊断评估为阴性的参与者是否有癌症诊断;全身成像(WBI)在达到诊断分辨率方面的应用;在诊断过程中需要达到诊断解决真阳性和假阳性结果的差异。在本分析的39名参与者中,82%(32/39)在初步评估后获得了诊断解决,其中78%(25/32)通过CSO预测指导的随访获得了解决。18%(7/39)的患者需要对持续的临床怀疑癌症进行额外的评估,所有患者都获得了解决(3例有癌症,4例无癌症)。在检测到的癌症信号病例中,WBI仅对诊断分辨率有49%的贡献。大约90%的真阳性和假阳性病例进行了影像学检查;更多的真阳性和假阳性(81.0%对38.9%)接受了非手术和/或手术治疗。总之,CSO预测导向的评估使大多数参与者能够诊断解决,尽管一些初始评估为阴性但持续怀疑癌症需要额外的测试。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Clinical Evaluation of Cancer Signal Origin Prediction and Diagnostic Resolution following Multicancer Early Detection Testing in the PATHFINDER Study.

Clinical Evaluation of Cancer Signal Origin Prediction and Diagnostic Resolution following Multicancer Early Detection Testing in the PATHFINDER Study.

Clinical Evaluation of Cancer Signal Origin Prediction and Diagnostic Resolution following Multicancer Early Detection Testing in the PATHFINDER Study.

Clinical Evaluation of Cancer Signal Origin Prediction and Diagnostic Resolution following Multicancer Early Detection Testing in the PATHFINDER Study.

Blood-based multicancer early detection (MCED) tests represent a new approach for cancer detection. To gain insights into the utility of various approaches of evaluating a cancer signal detected (CSD) test result, we evaluated diagnostic journeys of a subset of 6,662 participants in PATHFINDER who had a CSD on both an initial and refined version of an MCED test that also provided a prediction of cancer signal origin (CSO). We sought to determine whether CSO prediction-guided diagnostic evaluations led to diagnostic resolution; whether participants with known risk factors for cancer beyond age alone and a negative initial diagnostic evaluation had a cancer diagnosis during study follow-up; the utility of whole-body imaging in reaching diagnostic resolution; and differences in the diagnostic journeys needed to reach diagnostic resolution for both true- and false-positive results. Of the 39 participants in this analysis, 82% (32/39) achieved diagnostic resolution after the initial evaluation, including 78% (25/32) who reached resolution specifically with a CSO prediction-directed workup. Eighteen percent (7/39) required additional evaluation for persistent clinical suspicion of cancer, all of whom achieved resolution (3 with and 4 without cancer). Whole-body imaging contributed to diagnostic resolution in only 49% of CSD cases. Approximately 90% of true- and false-positive cases had imaging tests; more true positives versus false positives (81.0% vs. 38.9%) had nonsurgical and/or surgical procedures. In conclusion, CSO prediction-directed evaluations enabled diagnostic resolution for most participants, although some with negative initial evaluations but persistent suspicion of cancer required additional testing.

Prevention relevance: MCED testing has the potential to increase detection of cancer at earlier stages. As MCED testing is a new technology, there are few data on the diagnostic journeys patients undergo following testing. We observed that for most patients, CSO prediction-directed workups were efficient, leading to diagnostic resolution after initial evaluation.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信